

Prof. Andrea Calcagno



Current position Since October 2020 Associate Professor of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy.

Education Infectious Diseases Specialist since December 2007; graduated with honours at the University of Torino with a dissertation on the pharmacogenetics of nevirapine entitled "Effects of Cytochrome P450 2B6 Single Nucleotide Polymorphisms on the pharmacokinetic profile of nevirapine in a heterogenous cohort of HIV-infected patients".

Diploma in Tropical Medicine & Hygiene (DTM&H) at the Mahidol University, Bangkok, Thailand during 2006.

Graduated with honours in Medicine and Surgery at the University of Torino, Torino, Italy with a dissertation on antibiotic resistance in Intensive Care Units.

Admitted to the college of Physicians of Torino on the 19th December 2003: Licence number 20030.

Working Experience

October 2012 - September 2020 Temporary Assistant Professor in Infectious Diseases ("RTD-B" since October 2017), Department of Medical Sciences, University of Turin.

Temporary Research Fellow at the University of Torino, Department of Infectious Diseases (March 2008- March 2012): shifts as Infectious Diseases Consultant and work as Clinical Researcher. Receiving a grant from the University of Torino for a research project entitled "Pharmacokinetics and Pharmacogenetics of raltegravir".

Six months (October 2006 – April 2007) and then one month (February 2009) in a rural hospital in Burundi as responsible of Paediatric and Malnourished children ward (50 beds) and HIV clinic.

Since October 2003 working in the HIV Clinic of the "Ospedale Amedeo di Savoia" in Torino mainly researching pharmacokinetics and pharmacodynamics of antiretroviral drugs. Participated in the conduction of phase II and phase III Clinical Trials.

During August 2003 one month attendance in the Internal Medicine ward of the University Hospital in Khartoum (Sudan).

2001/2 medical course attended at the University of Cordoba, Cordoba, Spain.

Spoken Languages

Good knowledge of English and Spanish, basic knowledge of French. Italian as mother tongue.

Teaching Experience

From the academic year 2013/2014 responsible of the Infectious Diseases course at the Nursing School and from the academic year 2017/2018 co-responsible of the Infectious Disease course at the School of Medicine and Surgery, University of Torino. Since 2007 participates in the preparation and conduction of lectures during the Infectious Diseases Course at the University of Torino (both to Medical Students and Nursing school students). Since 2012 teaching in the post-graduate school in Infectious Diseases at the University of Torino.

Since the academic year 2021/2022 teaching in the PhD Programme in Experimental Medicine and Therapy, University of Torino.

**Ordinary
Professor
Qualification
Appointments**

National Scientific Qualification (art.16 of the law 30 December 2010, n.240) for Ordinary Professor obtained on October 31st 2018 (and valid until October 30th, 2024).

2015-2019 Member of the Governing Council of the Italian Society of Infectious Diseases and Tropical Medicine (SIMIT).

Editorial Board

Since 2018, Academic Editor of "PlosOne".

Since 2017, Coordinator of the Study group on Mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine (SIMIT).

Since 2017 in the Scientific Committee of "IRENE" (Italian Registry of Pulmonary non tubercular Mycobacteria).

Since 2015 member of the GEPPPO (GEriatric Patients living with HIV/AIDS: a Prospective Multidimensional cOhort) Study Group and from 2017 in the Scientific Board of the cohort.

Since 2015, Associate Editor of "Le Infezioni in Medicina".

Since 2015, Vice Editor of "Infectious Diseases and Tropical Medicine".

Since 2015, in the Scientific Committee of the ICONA foundation (Italian Cohort Naïve Antiretrovirals).

**Conference
Organization**

Since 2013, Associate Editor of "BMC Infectious Diseases" Journal.

Since 2018, Member of the Organizing Committee of the International "Antivirals PK Workshop".

Member of the Scientific Committee of the Italian Conference on AIDS and Retroviruses in the years 2013, 2016, 2017, 2018, 2019, 2020, 2021, 2022 and 2023.

Guidelines

Since 2012 member of the HIV/AIDS expert Panel writing the Italian Guidelines on the use of antiretroviral drugs and on the management of HIV-positive patients.

**International
Collaborations**

Since 2014, Collaboration with the Infectious Disease Institute, Makerere University, Kampala, Uganda. Capacity building for the creation of a Laboratory of Pharmacogenetics in Uganda and conduction of phase IV studies.

He received three Erasmus + projects (in collaboration with the Department of Social Sciences) for the years 2019-2022, 2020-2023 and 2022-2025 for promoting the

exchange between the University of Torino and the Makerere University. Since 2020 in the organizing committee of the ToAfrica Summer School (<https://www.toafrica.it>).

Awards

- Winner of the "ICAR CROI Award 2012" for young Italian researchers for the project entitled "Determinants of Tenofovir Plasma Trough Concentrations: a Cross-sectional Analysis in the Clinical Setting" (Calcagno A et al. 19th Conference on Retroviruses and Opportunistic Infections, 5-8 Marzo 2012, P603).
- Winner of the "ICAR CROI Award 2013" for young Italian researchers for the project entitled "Cerebrospinal Fluid Viral and Neurodegenerative Markers in HIV-positive Very Late-presenters." Calcagno A et al. 20th Conference on Retroviruses and Opportunistic Infections, 3-6 Marzo 2013, Atlanta, GE, USA. P438).
- Winner of the "ICAR CROI Award 2014" for young Italian researchers for the project entitled "ABCC4 3348 T>C SNP Affects Tenofovir Urinary Output in HIV-Positive Patients". (Calcagno A, et al. 21st Conference on Retroviruses and Opportunistic Infections, March 3-6 2014, Boston, MA, USA. P 503).
- Winner of the "ICAR CROI Award 2015" for young Italian researchers for the project entitled "Neurocognitive Screening Tests Are Associated with Cardiovascular Risk and VACS scores" (Calcagno A, et al. 22nd Conference on Retroviruses and Opportunistic Infections, february 23-26, 2015, Seattle, WA, USA. P487).
- Winner of the "ICAR CROI Award 2016" for young Italian researchers for the project entitled "Predicting Drug Discontinuation in TDF-Tolerant Patients: A Prospective PK/PG Study" (Calcagno A, et al. 23rd Conference on Retroviruses and Opportunistic Infections. Boston, MA, US. February 22-25, 2016. P426).
- Winner of the special jury "ICAR CROI Award 2017" for young Italian researchers for the project entitled "Discordant HIV RNA in Olfactory Mucosa of HIV-positive Patients" (Calcagno A, et al. 24th Conference on Retroviruses and Opportunistic Infections, February 13-16, 2017, Seattle, WA, USA. P379).

Fund Raising

- "Ricerca Finalizzata 2013": 225.246 € for the network projects NET-2013-02355333-4 "Plasma, intracellular and tissue concentrations reached by a multi-target antiretroviral treatment during the treatment of patients with primary HIV infection: a pharmacokinetic/pharmacodynamic study".
- BMS grant support 2014: 20000 € for the project "Intracellular penetration of antiretrovirals into astrocytes: an *in vitro* study".
- Gilead Fellowship 2014: 15000 € for the project "Antiretroviral toxicity on astrocytes: an *in vitro* and *in vivo* study".
- Gilead Fellowship 2012: 25000 € for the project "Determinants of proximal tubular dysfunction in HIV-positive patients: a cross-sectional analysis in patients above 50 years of age"

Orcid ID

0000-0003-2534-8815

Publications

1. Cusato J, Avataneo V, Antonucci M, Trunfio M, Marinaro L, Palermiti A, Manca A, Di Perri G, Mula J, Bonora S, D'Avolio A, Calcagno A. Antiretroviral Levels in

- the Cerebrospinal Fluid: The Effect of Inflammation and Genetic Variants. **Diagnostics (Basel). 2023.**
2. Cusato J, Borghetti A, Teti E, Milesi M, Tettoni MC, Bonora S, Trunfio M, D'Avolio A, Compagno M, Di Giambenedetto S, Di Perri G, Calcagno A. Dolutegravir Discontinuation for Neuropsychiatric Symptoms in People Living with HIV and Their Outcomes after Treatment Change: A Pharmacogenetic Study. **Metabolites. 2022.**
 3. Manzini PM, Ciccone G, De Rosa FG, Cavallo R, Ghisetti V, D'Antico S, Galassi C, Saccona F, Castiglione A, Birocco N, Francisci T, Hu H, Pecoraro C, Danielle F, Labanca L, Bordiga AM, Lorenzi M, Camisasca G, Giachino O, Pagliarino M, Ottone P, Scuvera ITD, Guaschino R, Freilone R, Berti P, Pittaluga F, Avolio M, Costa C, Raso S, Nucci A, Milan M, Baffa A, Russo A, Tornello A, Maddalena L, Delios G, Marletto FP, De Micheli AG, Mattei A, Baldassano S, Canta F, Russo ML, Bergamo D, Vitale F, Liccardi MM, Chinaglia A, Calcagno A, Converso M, Aldieri C, Libanore V, Blangetti I, Benedetti V, Mitola B, Scozzari G; PLACO COVID Study Group. Convalescent or standard plasma versus standard of care in the treatment of COVID-19 patients with respiratory impairment: short and long-term effects. A three-arm randomized controlled clinical trial. **BMC Infect Dis. 2022**
 4. Sciascia S, Arbrile M, Trunfio M, Calcagno A, Radin M, Roccatello D, Lembo D, Civra A. The role of bacteria and viruses in Behçet syndrome: Should we move towards new paradigms? **Autoimmun Rev. 2022**
 5. Trunfio M, Di Girolamo L, Ponzetta L, Russo M, Burdino E, Imperiale D, Atzori C, Di Perri G, Calcagno A. Seropositivity and reactivations of HSV-1, but not of HSV-2 nor VZV, associate with altered blood-brain barrier, beta amyloid, and tau proteins in people living with HIV. **J Neurovirol. 2022**
 6. Riccardi N, Antonello RM, Giacomelli A, Saderi L, Canetti D, Pallotto C, Mazzaferri F, Degli Antoni AM, Cardellino C, Motta I, Calcagno A, Falcone M, Trezzi M, Comelli A, Pascale R, Merli M, Binda F, Angheben A, Sotgiu G, Gobbi F, Nozza S. The challenge of infectious diseases consultations in the emergency department: an Italian nationwide survey. **New Microbiol. 2022.**
 7. De Nicolò A, Calcagno A, Motta I, De Vivo E, D'Avolio A, Di Perri G, Wiesner L, Ebrahim IE, Maartens G, Orrell C, McIlleron H. The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study. **Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0013622.**
 8. Cusato J, Palermi A, Manca A, Mula J, Antonucci M, De Nicolò A, Allegra S, De Francia S, Chiara F, Di Perri G, Rosa FG, Calcagno A, D'Avolio A. Antifungal Drug Plasma Exposures: A Possible Contribution of Vitamin D-Related Gene Variants. **Pharmaceuticals (Basel). 2022 May 20;15(5):630.**
 9. Ochoa-Azze R, Chang-Monteagudo A, Climent-Ruiz Y, Macías-Abraham C, Valenzuela-Silva C, de Los Ángeles García-García M, Jerez-Barceló Y, Triana-Marrero Y, Ruiz-Villegas L, Dairon Rodríguez-Prieto L, Guerra-Chaviano PP, Sánchez-Ramírez B, Hernández-García T, Orosa-Vázquez I, Díaz-Hernández M, Chiodo F, Calcagno A, Ghisetti V, Rodríguez-Acosta M, Noa-Romero E, Enríquez-Puertas J, Ortega-León D, Valdivia-Álvarez I, Delahanty-Fernández A, Palenzuela-Díaz A, Rodríguez-Noda L, González-Mugica R, Valdés-Balbín Y, García-Rivera D, Verez-Bencomo V. Safety and immunogenicity of the FINLAY-FR-1A vaccine in

COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial. **Lancet Respir Med.** **2022** Aug;10(8):785-795.

10. De Benedetto I, Barco A, Rossi M, Lapadula G, Lupia T, Bonfanti P, Bonora S, Di Perri G, Calcagno A. BCGitis after Bacille Calmette-Guerin intravesical administration from two referral centers: clinical characteristics and risk factors. **Infez Med.** **2022** Jun 1;30(2):242-246.
11. Trunfio M, Scabini S, Ruggie W, Bonora S, Di Perri G, Calcagno A. Concurrent and Subsequent Co-Infections of *Clostridioides difficile* Colitis in the Era of Gut Microbiota and Expanding Treatment Options. **Microorganisms.** **2022** Jun 23;10(7):1275.
12. Mastorino L, Dapavo P, Trunfio M, Avallone G, Rubatto M, Calcagno A, Ribero S, Quaglino P. Risk of Reactivation of Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: A Retrospective Cohort from a Tertiary Care Centre in Northern Italy. **Acta Derm Venereol.** **2022** Sep 6. doi: 10.2340/actadv.v102.1982.
13. Trunfio M, Portesani F, Vicinanza S, Nespoli P, Traverso F, Cortese G, Bonora S, Calcagno A, Di Perri G. Real-life Evidence of Lower Lung Virulence in COVID-19 Inpatients Infected with SARS-CoV-2 Omicron Variant Compared to Wild-type and Delta SARS-CoV-2 Pneumonia. **Lung.** **2022** Oct;200(5):573-577.
14. Ferrara M, Cusato J, Salvador E, Trentalange A, Alcantarini C, Trunfio M, Cannizzo ES, Bono V, Nozza S, De Nicolò A, Ianniello A, De Vivo E, D'Avolio A, Di Perri G, Bonora S, Marchetti G, Calcagno A. Inflammation and Intracellular Exposure of Dolutegravir, Darunavir, Tenofovir and Emtricitabine in People living with HIV. **Br J Clin Pharmacol.** **2022** Sep 17.
15. Trunfio M, Atzori C, Pasquero M, Di Stefano A, Vai D, Nigra M, Imperiale D, Bonora S, Di Perri G, Calcagno A. Patterns of Cerebrospinal Fluid Alzheimer's Dementia Biomarkers in People Living with HIV: Cross-Sectional Study on Associated Factors According to Viral Control, Neurological Confounders and Neurocognition. **Viruses.** **2022** Apr 4;14(4):753.
16. Trunfio M, Richiardi L, Alladio F, Staffilano E, Longo B, Venuti F, Ghisetti V, Burdino E, Bonora S, Vineis P, Di Perri G, Calcagno A. Determinants of SARS-CoV-2 Contagiousness in Household Contacts of Symptomatic Adult Index Cases. **Front Microbiol.** **2022** Apr 1;13:829393.
17. De Nicolò A, Calcagno A, Motta I, De Vivo E, D'Avolio A, Di Perri G, Wiesner L, Ebrahim IE, Maartens G, Orrell C, McIlleron H. The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study. **Antimicrob Agents Chemother.** **2022** May 18:e0013622.
18. Cusato J, Palermi A, Manca A, Mula J, Antonucci M, De Nicolò A, Allegra S, De Francia S, Chiara F, Di Perri G, Rosa FG, Calcagno A, D'Avolio A. Antifungal Drug Plasma Exposures: A Possible Contribution of Vitamin D-Related Gene Variants. **Pharmaceuticals (Basel).** **2022** May 20;15(5):630.
19. Stroffolini G, Rossi L, Lupia T, Faraoni S, Paltrinieri G, Lipani F, Calcagno A, Bonora S, Di Perri G, Calleri G. Trichinella britovi outbreak in Piedmont, North-West Italy, 2019-2020: Clinical and epidemiological insights in the one health perspective. **Travel Med Infect Dis.** **2022**.

20. Avataneo V, Palermiti A, De Nicolò A, Cusato J, Giussani G, Calcagno A, D'Avolio A. Monthly Increase in Vitamin D Levels upon Supplementation with 2000 IU/Day in Healthy Volunteers: Result from "Integriamoci", a Pilot Pharmacokinetic Study. **Molecules**. **2022**. Feb 3;27(3):1042. Impact Factor 4.412.
21. Babiloni C, Del Percio C, Lizio R, Lopez S, Pennica A, Roma P, Correr V, Cucciolla F, Toma G, Soricelli A, Di Campli F, Aceti A, Teti E, Sarmati L, Crocetti G, Ferri R, Lorenzo I, Galli M, Negri C, Angarano G, Saracino A, Lepore L, Di Pietro M, Fusco FM, Vullo V, D'Ettore G, Pagliano P, Di Flumeri G, Celesia BM, Gentilini Cacciola E, Di Perri G, Calcagno A, Stocchi F, Ferracuti S, Onorati P, Andreoni M, Noce G. Parietal intrahemispheric source connectivity of resting-state electroencephalographic alpha rhythms is abnormal in Naïve HIV patients. **Brain Res Bull**. **2022**. Apr;181:129-143. Impact factor 4.079.
22. Barco A, Orlando S, Stroffolini G, Pirriatore V, Lazzaro A, Vai D, Guastamacchia G, Noce G, Atzori C, Trunfio M, Bonora S, Di Perri G, Calcagno A. Correlations between cerebrospinal fluid biomarkers, neurocognitive tests, and resting-state electroencephalography (rsEEG) in patients with HIV-associated neurocognitive disorders. **J Neurovirol**. **2022**. Impact Factor 2.643.
23. Trunfio M, De Francesco D, Vai D, Medina C, Milesi M, Domini S, Alcantarini C, Imperiale D, Bonora S, Di Perri G, Calcagno A. Screening Accuracy of Mini Addenbrooke's Cognitive Examination Test for HIV-Associated Neurocognitive Disorders in People Ageing with HIV. **AIDS Behav**. **2022**. Impact Factor 3.895.
24. Trunfio M, Verga F, Ghisetti V, Burdino E, Emanuele T, Bonora S, Di Perri G, Calcagno A. Clinical Phenotype and Contagiousness of Early Breakthrough SARS-CoV-2 Infections after BNT162b2 COVID-19 mRNA Vaccine: A Parallel Cohort Study in Healthcare Workers. **Vaccines (Basel)**. **2021**. Impact factor 4.422.
25. Stroffolini G, Segala FV, Lupia T, Faraoni S, Rossi L, Tomassone L, Zanet S, De Rosa FG, Di Perri G, Calcagno A. Serology for *Borrelia* spp. in Northwest Italy: A Climate-Matched 10-Year Trend. **Life (Basel)**. **2021**. Impact Factor 3.817.
26. Calcagno A, Celani L, Trunfio M, Orofino G, Imperiale D, Atzori C, Arena V, d'Ettore G, Guaraldi G, Gisslen M, Di Perri G. Alzheimer Dementia in People Living With HIV. **Neurol Clin Pract**. **2021**. Impact Factor 1.241.
27. Stroffolini G, Guastamacchia G, Audagnotto S, Atzori C, Trunfio M, Nigra M, Di Stefano A, Di Perri G, Calcagno A. Low cerebrospinal fluid Amyloid- β 1-42 in patients with tuberculous meningitis. **BMC Neurol**. **2021**. Impact Factor 2.293.
28. TB/COVID-19 Global Study Group. Tuberculosis and COVID-19 co-infection: description of the global cohort. **Eur Respir J**. **2021** [Epub ahead of print] Impact factor 16.670.
29. Ulfhammer G, Edén A, Antinori A, Brew BJ, Calcagno A, Cinque P, De Zan V, Hagberg L, Lin A, Nilsson S, Oprea C, Pinnetti C, Spudich S, Trunfio M, Winston A, Price RW, Gisslén M. Cerebrospinal Fluid viral load across the spectrum of untreated HIV-1 infection: a cross-sectional multi-center study. **Clin Infect Dis**. **2021** [Epub ahead of print] Impact factor 8.313.
30. Airolidi C, Calcagno A, Di Perri G, Valinotto R, Gallo L, Locana E, Trunfio M, Patrucco F, Vineis P, Faggiano F. Seroprevalence of SARS-CoV-2 Among Workers in Northern Italy. **Ann Work Expo Health**. **2021**. Impact factor 1.81
31. Trunfio M, Scabini S, Mornese Pinna S, Ruge W, Alcantarini C, Pirriatore V, Di Perri G, Bonora S, Castelnuovo B, Calcagno A. The Manifesto of

- Pharmacoenosis: Merging HIV Pharmacology into Pathocoenosis and Syndemics in Developing Countries. **Microorganisms**. 2021 Jul 31;9(8):1648. Impact factor 4.128.
32. Cusato J, Mula J, Palermiti A, Manca A, Antonucci M, Avataneo V, De Vivo ED, Ianniello A, Calcagno A, Di Perri G, De Nicolò A, D'Avolio A. Seasonal Variation of Antiretroviral Drug Exposure during the Year: The Experience of 10 Years of Therapeutic Drug Monitoring. **Biomedicines**. 2021 Sep 12;9(9):1202.
33. Parietti M, Trunfio M, Delmonte S, Conti L, Trentalange A, Bonora S, Calcagno A, Ribero S. Efflorescence of acquired epidermodysplasia verruciformis due to immune reconstitution inflammatory syndrome-like mechanisms following anti-HPV vaccination in a HIV-positive patient. **Int J STD AIDS**. 2021 Oct 11:9564624211048343.
34. Avallone G, Trunfio M, Mastorino L, Agostini A, Merli M, Rubatto M, Caracciolo D, Calcagno A, Senetta R, Fierro MT, Quaglino P, Ribero S. Case Report: Atypical Cutaneous Presentation of Human T-cell Lymphotropic Virus Type 1-Related Adult T-cell Lymphoma. **Am J Trop Med Hyg**. 2021 Oct 11:tpmd210630.
35. Focà E, Calcagno A, Calza S, Renzetti S, Chiesa A, Siano M, De Socio G, Piconi S, Orofino G, Madeddu G, Cattelan AM, Nozza S, Ferrara M, Milic J, Celesia BM, Castelli F, Guaraldi G. Durability of Integrase STRand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPPPO cohort. **PLoS One**. 2021 Oct 13;16(10):e0258533.
36. Cusato J, Tempestilli M, Calcagno A, Vergori A, Piselli P, Antonucci M, Avataneo V, Palermiti A, Notari S, Antinori A, Di Perri G, Agrati C, D'Avolio A. Vitamin D as Modulator of Drug Concentrations: A Study on Two Italian Cohorts of People Living with HIV Administered with Efavirenz. **Nutrients**. 2021 Oct 12;13(10):3571.
37. Clerico M, Dogliotti I, Calcagno A, Grimaldi D, Leone S, Ragaini S, Boffini M, Caracciolo D, Ferrero S, Barbero C, Zanotto E, Stroffolini G, Cavallo R, Rinaldi M, Bruno B, Cavallo F. COVID-19 in a Post-transplant Heart Recipient Who Developed Aggressive Lymphoma: A Biphasic Course During Rituximab Treatment. **Hemasphere** 2021.
38. Chan TY, De Zan V, Gregg A, Alagaratnam J, Gerevini S, Antinori A, Monforte AD, Saracino A, Trunfio M, Everitt A, Rackstraw S, Marta M, Calcagno A, Cinque P, Winston A. Cerebrospinal fluid HIV RNA escape symptomatology. **AIDS** 2021.
39. De Nicolò A, Manca A, Ianniello A, Palermiti A, Calcagno A, Ferrara M, Antonucci M, Cusato J, Avataneo V, De Vivo E, Bonora S, De Rosa FG, Di Perri G, D'Avolio A. Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma. **Pharmaceuticals (Basel)** 2021.
40. De Nicolò A, Avataneo V, Cusato J, Palermiti A, Mula J, De Vivo E, Antonucci M, Bonora S, Calcagno A, Di Perri G, De Rosa FG, D'Avolio A. Analytical Validation and Clinical Application of Rapid Serological Tests for SARS-CoV-2 Suitable for Large-Scale Screening. **Diagnostics (Basel)** 2021.
41. Caligaris G, Trunfio M, Ghisetti V, Cusato J, Nigra M, Atzori C, Imperiale D, Bonora S, Di Perri G, Calcagno A. Blood-Brain Barrier Impairment in Patients Living with HIV: Predictors and Associated Biomarkers. **Diagnostics (Basel)**. 2021.

42. Calcagno A, Trunfio M, D'Avolio A, Di Perri G, Bonora S. The impact of age on antiretroviral drug pharmacokinetics in the treatment of adults living with HIV. **Expert Opin Drug Metab Toxicol** 2021.
43. Calcagno A, de Nicolò A, Pizzi C, Trunfio M, Tettoni C, Ferrara M, Alcantarini C, Trentini L, D'Avolio A, Di Perri G, Bonora S. Medication burden and clustering in people living with HIV undergoing therapeutic drug monitoring. **Br J Clin Pharmacol** 2021.
44. Trunfio M, Calcagno A, Bonora S, Di Perri G. Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases. **Lancet Infect Dis** 2021.
45. Trunfio M, Longo BM, Alladio F, Venuti F, Cerutti F, Ghisetti V, Bonora S, Di Perri G, Calcagno A. On the SARS-CoV-2 "Variolation Hypothesis": No Association Between Viral Load of Index Cases and COVID-19 Severity of Secondary Cases. **Front Microbiol** 2021.
46. Ancona G, Merlini E, Tincati C, Barassi A, Calcagno A, Augello M, Bono V, Bai F, Cannizzo ES, d'Arminio Monforte A, Marchetti G. Long-Term Suppressive cART Is Not Sufficient to Restore Intestinal Permeability and Gut Microbiota Compositional Changes. **Front Immunol** 2021.
47. Trunfio M, Venuti F, Alladio F, Longo BM, Burdino E, Cerutti F, Ghisetti V, Bertucci R, Picco C, Bonora S, Di Perri G, Calcagno A. Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients. **Viruses** 2021.
48. Guaraldi G, Calza S, Milic J, Calcagno A, Focà E, Rota M, Renzetti S, Celotti A, Siano M, Celesia BM, Piconi S, de Socio GV, Cattelan AM, Orofino G, Riva A, Nozza S, di Perri G. Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV. **AIDS** 2021.
49. Lin SP, Calcagno A, Letendre SL, Ma Q. Clinical Treatment Options and Randomized Clinical Trials for Neurocognitive Complications of HIV Infection: Combination Antiretroviral Therapy, Central Nervous System Penetration Effectiveness, and Adjuvants. **Curr Top Behav Neurosci** 2021.
50. Trentalange A, Borgogno E, Motta I, Antonucci M, Pirriatore V, Costa C, Rossi G, Barco A, De Nicolò A, Piccioni P, D'Avolio A, Bonora S, Perri GD, Calcagno A. Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses? **Int J Antimicrob Agents** 2021.
51. The TB/COVID-19 Global Study Group. TB and COVID-19 co-infection: rationale and aims of a global study. **Int J Tuberc Lung Dis** 2021.
52. Trunfio M, Salvador E, Gaviraghi A, Audagnotto S, Marinaro L, Motta I, Casciaro R, Ghisetti V, Fava C, Bonora S, Di Perri G, Calcagno A; e-COVID Study Group. Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity. **Antivir Ther** 2021.
53. De Nicolò A, Ianniello A, Ferrara M, Avataneo V, Cusato J, Antonucci M, De Vivo E, Waitt C, Calcagno A, Trentalange A, Muccioli G, Bonora S, Di Perri G, D'Avolio A. Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV. **Pharmaceuticals (Basel)** 2020.
54. Calcagno A, Dal Conte I, Cattaneo D, Testi R, Mistrangelo M, Gervasoni C, de Nicolò A, Bonora S, D'Avolio A, Di Perri G. Low Tenofovir Plasma Exposure in HIV

Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders. **Antimicrob Agents Chemother** 2020.

55. Maggiolo F, Bandera A, Bonora S, Borderi M, Calcagno A, Cattelan A, Cingolani A, Gianotti N, Lichtner M, Lo Caputo S, Madeddu G, Maggi P, Marchetti GC, Maserati R, Nozza S, Rusconi S, Zazzi M, Di Biagio A. Enhancing care for people living with HIV: current and future monitoring approaches. **Expert Rev Anti Infect Ther** 2020.
56. Trunfio M, Salvador E, Cabodi D, Marinaro L, Alcantarini C, Gaviraghi A, Trentalange A, Lipani F, Sciascia S, Roccatello D, Bonora S, Di Perri G, Calcagno A; e-COVID Study group. Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection. **Thromb Res** 2020.
57. Calcagno A, Ghisetti V, Emanuele T, Trunfio M, Faraoni S, Boglione L, Burdino E, Audagnotto S, Lipani F, Nigra M, D'Avolio A, Bonora S, Di Perri G. Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy. **Emerg Infect Dis** 2020.
58. Calcagno A, Ghisetti V, Burdino E, Trunfio M, Alice T, Boglione L, Bonora S, Di Perri G. Coinfection with other respiratory pathogens in COVID-19 patients. **Clin Microbiol Infect** 2020.
59. De Benedetto I, Trunfio M, Guastamacchia G, Bonora S, Calcagno A. A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs. **J Neurovirol** 2020.
60. Calcagno A, Moltò J, Borghetti A, Gervasoni C, Milesi M, Valle M, Avataneo V, Alcantarini C, Pla-Junca F, Trunfio M, D'Avolio A, Di Giambenedetto S, Cattaneo D, Di Perri G, Bonora S. Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV. **Clin Pharmacokinet** 2020.
61. Trunfio M, Ruge W, Mighetto L, Vai D, Atzori C, Nigra M, Domini S, Borgogno E, Guastamacchia G, Bonora S, Di Perri G, Calcagno A. Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV. **AIDS**. 2020.
62. Taramasso L, Fabbiani M, Nozza S, De Benedetto I, Bruzzesi E, Mastrangelo A, Pinnetti C, Calcagno A, Ferrara M, Bozzi G, Focà E, Quiros-Roldan E, Ripamonti D, Campus M, Celesia BM, Torti C, Cosco L, Di Biagio A, Rusconi S, Marchetti G, Mussini C, Gulminetti R, Cingolani A, d'Ettorre G, Madeddu G, Franco A, Orofino G, Squillace N, Muscatello A, Gori A, Antinori A, Tambussi G, Bandera A; INACTION study group. Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (INACTION) cohort. **HIV Med** 2020.
63. Draid AN, Gawali R, Betha TP, Sharma AK, Medisetty M, Natrajan K, Kulkarni MM, Saraf CK, Mahajan US, Kore SD, Rathod NM, Mahajan US, Letendre SL, Wadia RS, Calcagno A. Two treatment strategies for management of Neurosymptomatic cerebrospinal fluid HIV escape in Pune, India. **Medicine (Baltimore)** 2020.
64. Sciascia S, Aprà F, Baffa A, Baldovino S, Boaro D, Boero R, Bonora S, Calcagno A, Cecchi I, Cinnirella G, Converso M, Cozzi M, Crosasso P, De Iaco F, Di Perri G, Eandi M, Fenoglio R, Giusti M, Imperiale D, Imperiale G, Livigni S, Manno E, Massara C, Milone V, Natale G, Navarra M, Oddone V, Osella S, Piccioni P, Radin M, Roccatello D, Rossi D. Pilot prospective open, single-arm multicentre study

- on off-label use of tocilizumab in patients with severe COVID-19. **Clin Exp Rheumatol 2020.**
65. Muscatello A, Nozza S, Fabbiani M, De Benedetto I, Ripa M, Dell'acqua R, Antinori A, Pinnetti C, Calcagno A, Ferrara M, Focà E, Quiros-Roldan E, Ripamonti D, Campus M, Maurizio Celesia B, Torti C, Cosco L, Di Biagio A, Rusconi S, Marchetti G, Mussini C, Gulminetti R, Cingolani A, D'ettore G, Madeddu G, Franco A, Orofino G, Squillace N, Gori A, Tambussi G, Bandera A; Inaction Study Group. Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection-Results of Italian Network of ACuTe HIV InfectiON (IN ACTION) Retrospective Study. **Pathog Immun 2020.**
66. Mornese Pinna S, Trunfio M, Imperiale D, Calcagno A. JC virus DNA in cerebrospinal fluid: insight into clinical significance. **Diagn Microbiol Infect Dis 2020.**
67. Lupia T, Milia MG, Atzori C, Gianella S, Audagnotto S, Imperiale D, Mighetto L, Pirriatore V, Gregori G, Lipani F, Ghisetti V, Bonora S, Di Perri G, Calcagno A. Presence of Epstein-Barr virus DNA in cerebrospinal fluid is associated with greater HIV RNA and inflammation. **AIDS 2020.**
68. Joseph SB, Trunfio M, Kincer LP, Calcagno A, Price RW. What can characterization of cerebrospinal fluid escape populations teach us about viral reservoirs in the central nervous system? **AIDS 2019.**
69. Lwanga I, Nabaggala MS, Kiragga A, Calcagno A, Guaraldi G, Lamorde M, Castelnuovo B. Implementing routine physical function screening among elderly HIV-positive patients in Uganda. **AIDS Care 2019.**
70. Goletti D, Navarra A, Petruccioli E, Cimaglia C, Compagno M, Cuzzi G, De Carli G, Fondaco L, Franzetti F, Giannetti A, Gori A, Lapadula G, Lichtner M, Mastroianni CM, Mazzotta V, Orchi N, Pavone P, Piacentini D, Pirriatore V, Pontali E, Sarmati L, Spolti A, Tacconelli E, Galli M, Antinori A, Calcagno A, Girardi E. Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: A multicentre study promoted by the Italian Society of Infectious and Tropical Diseases. **Int J Infect Dis. 2020.**
71. Lupia T, Scabini S, Stroffolini G, Calcagno A. I have got you under my skin. **Infection 2020.**
72. Montrucchio C, De Nicolò A, D'Ettoire G, D'Ascenzo F, Lazzaro A, Tettoni M, D'Avolio A, Bonora S, Celani L, Di Perri G, Calcagno A. Serum Trimethylamine-N-oxide Concentrations in People Living with HIV and the Effect of Probiotic Supplementation. **Int J Antimicrob Agents. 2020.**
73. Costa C, Scabini S, Kaimal A, Kasozi W, Cusato J, Kafufu B, Borderi M, Mwaka E, Di Perri G, Lamorde M, Calcagno A, Castelnuovo B. Calcaneal quantitative ultrasound and urine retinol binding protein in HIV-positive antiretroviral-treated patients in Uganda: a pilot study. **J Infect Dis 2020.**
74. Calcagno A, Cusato J, Ferrara M, De Nicolò A, Lazzaro A, Manca A, D'Avolio A, Di Perri G, Bonora S. Antiretroviral concentrations in the presence and absence of valproic acid. **J Antimicrob Chemother 2020.**
75. Cusato J, Calcagno A, Marinaro L, Avataneo V, D'Avolio A, Di Perri G, Bonora S. Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients. **Pharmacogenomics J 2019.**

76. Focà E, Magro P, Guaraldi G, Riva A, Cattelan AM, De Socio GV, Costa C, Piconi S, Celesia BM, Nozza S, Orofino G, Castagna A, Di Perri G, Castelli F, [Calcagno A](#); GEPPPO (GERiatric Patients living with HIV/AIDS: a Prospective Multidimensional cOhort) Study Group. Elderly HIV-positive women: A gender-based analysis from the Multicenter Italian "GEPPPO" Cohort. **PLoS One** **2019**.
77. Trunfio M, Manini C, Trentalange A, Boghi A, Audagnotto S, Imperiale D, Taraglio S, Bonora S, Di Perri G, [Calcagno A](#). The "milky way" galaxy of HIV-related central nervous system immune reaction syndromes. **J Neurovirol** **2019**.
78. Di Stefano A, Alcantarini C, Atzori C, Lipani F, Imperiale D, Burdino E, Audagnotto S, Mighetto L, Milia MG, Di Perri G, [Calcagno A](#). Cerebrospinal fluid biomarkers in patients with central nervous system infections: a retrospective study. **CNS Spectr** **2019**.
79. Armenia D, Di Carlo D, Cozzi-Lepri A, [Calcagno A](#), Borghi V, Gori C, Bertoli A, Gennari W, Bellagamba R, Castagna A, Latini A, Pinnetti C, Cicalini S, Saracino A, Lapadula G, Rusconi S, Castelli F, Di Giambenedetto S, Andreoni M, Di Perri G, Antinori A, Mussini C, Ceccherini-Silberstein F, Monforte AD, Perno CF, Santoro MM; ICONA Foundation Study Group. Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen. **Antivir Ther** **2019**.
80. Cusato J, [Calcagno A](#), De Nicolò A, Mogyorosi K, D'Avolio A, Di Perri G, Bonora S. Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2. **Diagn Microbiol Infect Dis** **2019**.
81. Sekaggya-Wiltshire C, Chirehwa M, Musaazi J, von Braun A, Buzibye A, Muller D, Gutteck U, Motta I, [Calcagno A](#), Fehr JS, Kambugu A, Castelnuovo B, Lamorde M, Denti P. Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines? **Antimicrob Agents Chemother** **2019**.
82. Ssebambulidde K, Segawa I, Laker E, Lamorde M, Castelnuovo B, Nakasujja N, [Calcagno A](#). Symptomatic cerebrospinal fluid HIV-1 escape in two patients on second-line antiretroviral therapy in Uganda. **Oxf Med Case Reports**. **2019**. *Not Impacted*.
83. [Calcagno A](#), Cusato J, Sekaggya-Wiltshire C, von Braun A, Motta I, Turyasingura G, Castelnuovo B, Fehr J, Di Perri G, Lamorde M. The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Co-infected Patients in Uganda in the SOUTH Study. **Clin Pharmacol Ther** **2019**.
84. Pinzone MR, Ceccarelli M, Venanzi Rullo E, Maresca M, Bruno R, Condorelli F, Di Rosa M, Madeddu G, Focà E, [Calcagno A](#), Celesia BM, Cacopardo B, Nunnari G, Pellicanò GF. Circulating angiopoietin-like protein 2 levels are associated with decreased renal function in HIV+ subjects on cART: A potential marker of kidney disease. **Biomed Rep**. **2019**. *Not Impacted*.
85. Peyracchia M, Verardi R, Rubin SR, Abu-Assi E, Montrucchio C, Perl L, Grossomarra W, [Calcagno A](#), Omedè P, Montefusco A, Bonora S, Moretti C, D'Amico M, Mauro R, D'Ascenzo F. In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis. **J Cardiovasc Med (Hagerstown)** **2019**.
86. Mondì A, Cozzi-Lepri A, Tavelli A, Rusconi S, Vichi F, Ceccherini-Silberstein F, [Calcagno A](#), De Luca A, Maggiolo F, Marchetti G, Antinori A, d'Arminio Monforte A; Icona Foundation Study Group. Effectiveness of dolutegravir-based regimens

as either first-line or switch antiretroviral therapy: data from the Icona cohort. **J Int AIDS Soc 2019.**

87. Lupia T, Costa C, Forni N, Calcagno A. A "Tinea" immune reconstitution inflammatory syndrome in a HIV-positive patient starting combination antiretroviral treatment. **G Ital Dermatol Venereol 2019.**
88. Bertero L, Joseph SB, Trunfio M, Alice T, Catera S, Imperiale D, Cassoni P, Kincer LP, Pirriatore V, Ghisetti V, Amasio E, Zanusso G, Bonora S, Di Perri G, Calcagno A. HIV-1 detection in the olfactory mucosa of HIV-1 infected participants. **AIDS 2019.**
89. Borghetti A, Calcagno A, Lombardi F, Cusato J, Belmonti S, D'Avolio A, Ciccarelli N, La Monica S, Colafigli M, Delle Donne V, De Marco R, Tamburrini E, Visconti E, Di Perri G, De Luca A, Bonora S, Di Giambenedetto S. SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. **J Antimicrob Chemother 2018.**
90. Trunfio M, Pinnetti C, Focà E, Bai F, Maffongelli G, Celani L, Cinque P, Celotti A, Andreoni M, Monforte AD, D'Ettorre G, Antinori A, Calcagno A. Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities: is it time to assess the definitions? **AIDS 2018.**
91. Di Perri G, Calcagno A, Trentalange A, Bonora S. The clinical pharmacology of integrase inhibitors. **Expert Rev Clin Pharmacol 2018.**
92. Calcagno A, Fiumanò M, Zugna D, Cusato J, Montrucchio C, Marinaro L, Trentini L, Ferrara M, D'Avolio A, Pizzi C, Di Perri G, Bonora S. Tenofovir disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization? **Pharmacogenomics J 2019.**
93. von Braun A, Castelnuovo B, Ledergerber B, Cusato J, Buzibye A, Kambugu A, Fehr J, Calcagno A, Lamorde M, Sekaggya-Wiltshire C. High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment. **J Antimicrob Chemother 2019.**
94. Trentalange A, Prochet A, Imperiale D, Cusato J, Tettoni M, Nunnari G, Barco A, Bonora S, Di Perri G, Calcagno A. Cerebral white matter Hyperintensities in HIV-positive patients. **Brain Imaging Behav 2018.**
95. Aliberti S, Codecasa LR, Gori A, Sotgiu G, Spotti M, Di Biagio A, Calcagno A, Nardini S, Assael BM, Tortoli E, Besozzi G, Ferrarese M, Matteelli A, Girardi E, De Lorenzo S, Seia M, Gramegna A, Del Prato B, Terranova L, Oriano M, Sverzellati N, Mirsaeidi M, Chalmers JD, Haworth CS, Loebinger MR, Aksamit T, Winthrop K, Ringshausen FC, Previdi G, Blasi F; IRENE Network. The Italian registry of pulmonary non-tuberculous mycobacteria - IRENE: the study protocol. **Multidiscip Respir Med 2018. Not Impacted.**
96. Merlini E, Iannuzzi F, Calcagno A, Bai F, Trunfio M, d'Arminio Monforte A, Bonora S, Marchetti G. Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART). **J Neurovirol 2018.**
97. Scabini S, Trunfio M, Pirriatore V, Imperiale D, Audagnotto S, Bertucci R, Ghisetti V, Cinnirella G, Cistaro A, Perna M, Calcagno A, Di Perri G. Antiviral activity of maraviroc plus mirtazapine in a low-risk HIV-negative patient with progressive multifocal leukoencephalopathy. **Infez Med 2018. Not Impacted.**
98. Allegra S, Cardellino CS, Fatiguso G, Cusato J, De Nicolò A, Avataneo V, Bonora S, D'Avolio A, Di Perri G, Calcagno A. Effect of ABCC2 and ABCG2 Gene

- Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations. **J Clin Pharmacol 2018.**
99. Focà E, Cavaglià G, Rusconi S, Cascavilla A, Cenderello G, Re A, Casari S, van den Bogaart L, Zinzani PL, Caracciolo D, Di Perri G, Bonito A, Lucchini A, Cassola G, Viale P, Calcagno A. Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study. **HIV Med 2018.**
100. Peyracchia M, De Lio G, Montrucchio C, Omedè P, d'Ettore G, Calcagno A, Vullo V, Cerrato E, Pennacchi M, Sardella G, Manga P, GrossoMarra W, Vullo F, Fedele F, Biondi-Zoccai G, Moretti C, Vachiat A, Bonora S, Rinaldi M, Mancone M, D'Ascenzo F. Evaluation of coronary features of HIV patients presenting with ACS: The CUORE, a multicenter study. **Atherosclerosis 2018.**
101. Trunfio M, Vai D, Montrucchio C, Alcantarini C, Livelli A, Tettoni MC, Orofino G, Audagnotto S, Imperiale D, Bonora S, Di Perri G, Calcagno A. Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disorders. **HIV Med 2018.**
102. Focà E, Calcagno A, Bonito A, Cusato J, Domenighini E, D'Avolio A, Quiros Roldan E, Trentini L, Castelnuovo F, Di Perri G, Castelli F, Bonora S. Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir. **Antimicrob Agents Chemother 2018.**
103. Guaraldi G, Malagoli A, Calcagno A, Mussi C, Celesia BM, Carli F, Piconi S, De Socio GV, Cattelan AM, Orofino G, Riva A, Focà E, Nozza S, Di Perri G. The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 - 74 years and more than 75 years. **BMC Geriatr 2018.**
104. Calcagno A, Pinnetti C, De Nicolò A, Scarvaglieri E, Gisslen M, Tempestilli M, D'Avolio A, Fedele V, Di Perri G, Antinori A, Bonora S. Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administration. **Br J Clin Pharmacol. 2018.**
105. Bigliano P, Calcagno A, Lucchini A, Audagnotto S, Montrucchio C, Marinaro L, Alcantarini C, Ghisetti V, Di Perri G, Bonora S. The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment. **Antivir Ther 2018.**
106. Calcagno A, Barco A, Trunfio M, Bonora S. CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose. **Curr HIV/AIDS Rep 2018.**
107. Palazzo A, Trunfio M, Pirriatore V, Milesi M, De Nicolò A, Alcantarini C, D'Avolio A, Bonora S, Di Perri G, Calcagno A. Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid. **J Antimicrob Chemother 2017.**
108. Trunfio M, Joseph SB, Ghisetti V, Romito A, Martini C, Cusato J, Audagnotto S, Pesci Kincer L, Ferrara M, Sala A, Imperiale D, Di Perri G, Calcagno A. Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia. **J Neurovirol. 2017.**
109. Motta I, Calcagno A, Bonora S. Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? **Expert Opin Drug Metab Toxicol 2018.**

110. Cusato J, Allegra S, Nicolò A, Calcagno A, D'Avolio A. Precision medicine for HIV: where are we? **Pharmacogenomics**. 2018.
111. Motta I, Trunfio M, Calcagno A, Pirriatore V, Scabini S, Palazzo A, Audagnotto S, Fatiguso G, Liberini V, Bellò M, D'Avolio A, Di Perri G, Bonora S. Undetectable antimicrobial plasma concentrations in an HIV-positive patient with protein-losing enteropathy and chylothorax during *Mycobacterium genavense* and Leishmania abdominal infections. **J Antimicrob Chemother** 2017.
112. Focà E, Calcagno A, Bonito A, Simiele M, Domenighini E, D'Avolio A, Quiros Roldan E, Trentini L, Casari S, Di Perri G, Castelli F, Bonora S. Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients. **J Antimicrob Chemother** 2017.
113. Calcagno A, Piconi S, Focà E, Nozza S, Carli F, Montrucchio C, Cattelan AM, Orofino G, Celesia BM, Morena V, De Socio GV, Guaraldi G; GEPPPO (GERiatric Patients living with HIV/AIDS: a Prospective Multidimensional cOhort) Study Group. Role of Normalized T-Cell Subsets in Predicting Comorbidities in a Large Cohort of Geriatric HIV-infected Patient. **J Acquir Immune Defic Syndr** 2017.
114. Mornese Pinna S, Scarvaglieri E, Milia MG, Imperiale D, Ghisetti V, Audagnotto S, Prochet A, Lipani F, Bonora S, Di Perri G, Calcagno A. Detectable cerebrospinal fluid JCV DNA in late-presenting HIV-positive patients: beyond progressive multifocal leukoencephalopathy? **J Neurovirol** 2017.
115. Nozza S, Malagoli A, Maia L, Calcagno A, Focà E, De Socio G, Piconi S, Orofino G, Cattelan AM, Celesia BM, Gervasi E, Guaraldi G; GEPPPO Study Group. Antiretroviral therapy in geriatric HIV patients: the GEPPPO cohort study. **J Antimicrob Chemother** 2017.
116. Allegra S, Fatiguso G, Calcagno A, Baietto L, Motta I, Favata F, Cusato J, Bonora S, Di Perri G, D'Avolio A. Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics. **Pharmacogenomics** 2017.
117. Calcagno A, Lucchini A, Caracciolo D, Balbiano R, Bracchi M, Sordella F, Gregori G, Lipani F, Audagnotto S, Chiriotto M, Cavaglià G, Ghisetti V, Di Perri G, Bonora S. High Incidence of Infections in HIV-positive Patients Treated for Lymphoproliferative Disorders. **Curr HIV Res** 2017.
118. Calcagno A, Pagani N, Ariaudo A, Arduino G, Carcieri C, D'Avolio A, Marinaro L, Tettoni MC, Trentini L, Di Perri G, Bonora S. Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure. **J Antimicrob Chemother** 2017.
119. Biagini R, Montrucchio C, Calcagno A, Trentini L, Tettoni MC, Alcantarini C, Barco A, Trentalange A, Milesi M, Ferrara M, Bertucci R, Di Perri G, Bonora S. Geriatrics in HIV infection: multimorbidity, polypharmacy and primary prevention in patients above 65 years). **Journal of HIV and Ageing**. 2017. *Not Impacted*
120. Motta I, Allice T, Romito A, Ferrara M, Ecclesia S, Imperiale D, Ghisetti V, Di Perri G, Bonora S, Calcagno A. Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia. **Antivir Ther** 2017.
121. Motta I, Calcagno A, Baietto L, Bigliano P, Costa C, Baruffi K, Fatiguso G, D'Avolio A, Di Perri G, Bonora S. Pharmacokinetics of first-line antitubercular drugs in plasma and PBMCs. **Br J Clin Pharmacol** 2017.

122. Montrucchio C, Biagini R, Alcantarini C, Calcagno A, Barco A, Ferrara M, Milesi M, Costa C, Trentalange A, Trunfio M, Tettoni MC, Grosso Marra W, D'Ascenzo F, Ballocca F, Lonni E, Gili S, Vai D, Imperiale D, Gaita F, Bonora S, Di Perri G. Cardiovascular risk and neurocognitive deficits in HIV-positive individuals. **Infectious Diseases & Tropical Medicine** 2017. *Not Impacted*.
123. Calcagno A, Di Perri G, Bonora S. Treating HIV Infection in the Central Nervous System. **Drugs** 2017.
124. Armenia D, Di Carlo D, Calcagno A, Vendemiati G, Forbici F, Bertoli A, Berno G, Carta S, Continenza F, Fedele V, Bellagamba R, Cicalini S, Ammassari A, Libertone R, Zaccarelli M, Ghisetti V, Andreoni M, Ceccherini-Silberstein F, Bonora S, Di Perri G, Antinori A, Perno CF, Santoro MM. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. **J Antimicrob Chemother** 2016.
125. Marinaro L, Calcagno A, Ripamonti D, Cenderello G, Pirriatore V, Trentini L, Salassa B, Bramato C, Orofino G, D'Avolio A, Rizzi M, Di Perri G, Rusconi S, Bonora S. Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting. **J Clin Virol** 2016.
126. Guaraldi G, Menozzi M, Zona S, Calcagno A, Silva AR, Santoro A, Malagoli A, Dolci G, Mussi C, Mussini C, Cesari M, Khoo SH. Impact of polypharmacy on antiretroviral prescription in people living with HIV. **J Antimicrob Chemother** 2016.
127. Calcagno A, Romito A, Atzori C, Ghisetti V, Cardellino C, Audagnotto S, Scarvaglieri E, Lipani F, Imperiale D, Di Perri G, Bonora S. Blood Brain Barrier Impairment in HIV-Positive Naïve and Effectively Treated Patients: Immune Activation Versus Astrocytosis. **J Neuroimmune Pharmacol** 2016.
128. Sanfilippo C, Nunnari G, Calcagno A, Malaguarnera L, Blennow K, Zetterberg H, Di Rosa M. The chitinases expression is related to Simian Immunodeficiency Virus Encephalitis (SIVE) and in HIV encephalitis (HIVE). **Virus Res** 2016.
129. Calcagno A, Cusato J, D'Avolio A, Bonora S. Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs. **Clin Pharmacokinet** 2016.
130. Gili S, Mancone M, Ballocca F, Grosso Marra W, Calcagno A, D'Ettore G, Cannillo M, D'Ascenzo F, Orofino G, Marruncheddu L, Lonni E, Cinque A, Vullo F, Ceccarelli G, Vilardi I, Sardella G, Vullo V, Moretti C, Fedele F, Bonora S, Gaita F. Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study. **J Cardiovasc Med (Hagerstown)** 2016.
131. Ruggiero T, Burdino E, Calcagno A, Bonora S, Boglione L, Di Perri G, Ghisetti V. HCV NS3 naturally occurring variants in HIV/HCV coinfecting DAA-naïve patients: consideration for HCV genotyping resistance testing. **Infection** 2016.
132. Focà E, Nunnari G, Calcagno A. The good, the bad and the ugly: Determinants of antiretroviral-associated toxicities. *Future Virology* 2016.
133. Patti F, Calcagno A, Simiele M, Bonasso M, Di Perri G, D'Avolio A, Bonora S. Pharmacokinetics of an antiretroviral regimen in a patient unable to swallow solid oral dosage forms. **Am J Health Syst Pharm** 2016.
134. Calcagno A, Di Perri G, Bonora S. What do we know about tailoring treatment with tenofovir? **Pharmacogenomics** 2016.

135. Calcagno A, Simiele M, Motta I, Mornese Pinna S, Bertucci R, D'Avolio A, Di Perri G, Bonora S. Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients. **AIDS Res Hum Retroviruses** 2016.
136. Ballocca F, Gili S, D'Ascenzo F, Marra WG, Cannillo M, Calcagno A, Bonora S, Flammer A, Coppola J, Moretti C, Gaita F. HIV Infection and Primary Prevention of Cardiovascular Disease: Lights and Shadows in the HAART Era. **Prog Cardiovasc Dis** 2016.
137. Trentalange A, Calcagno A, Ghisetti V, Atzori C, Busolli P, Bonora S, Imperiale D. Clearance of cerebrospinal fluid JCV DNA with mirtazapine in a patient with progressive multifocal leukoencephalopathy and sarcoidosis. **Antivir Ther** 2016.
138. Gili S, Grosso Marra W, D'Ascenzo F, Lonni E, Calcagno A, Cannillo M, Ballocca F, Cerrato E, Pianelli M, Barbero U, Mancone M, DiNicolantonio JJ, Lavie CJ, Omedè P, Montefusco A, Bonora S, Gasparini M, Biondi-Zoccai G, Moretti C, Gaita F. Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis. **Eur Heart J** 2016.
139. Lucchini A, Lipani F, Costa C, Scarvaglieri M, Balbiano R, Carosella S, Calcagno A, Audagnotto S, Barbui AM, Brossa S, Ghisetti V, Dal Conte I, Caramello P, Di Perri G. Louseborne Relapsing Fever among East African Refugees, Italy, 2015. **Emerg Infect Dis.** 2016.
140. Cusato J, Tomasello C, Simiele M, Calcagno A, Bonora S, Marinaro L, Leggieri A, Allegra S, Di Perri G, D'Avolio A. Efavirenz pharmacogenetics in a cohort of Italian patients. **Int J Antimicrob Agents** 2015.
141. Motta I, Calcagno A, Baietto L, D'Avolio A, De Rosa FG, Bonora S. A probable drug-to-drug interaction between voriconazole and haloperidol in a slow CYP2C9 metabolizer. **Infez Med** 2015. *Not impacted.*
142. Bonora S, Calcagno A, Trentalange A, Perri GD. Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults. **Expert Opin Pharmacother** 2015.
143. Fatiguso G, Allegra S, Calcagno A, Baietto L, Motta I, Favata F, Cusato J, Bonora S, Perri GD, D'Avolio A. Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. **Int J Pharm.** 2015.
144. Calcagno A, Rostagno R, Arnaudo I, Zanusso G, Bonora S, Lucchini A, Maiello A, Dal Conte I, Meoli I, Ferrari S, Monaco S, Rizzuto N, Di Perri G. CSF 14-3-3 protein and its ζ isoform are prognostic markers in HIV positive patients with CNS disease. **Infectious Diseases & Tropical Medicine** 2015. *Not Impacted.*
145. Calcagno A, Cusato J, Marinaro L, Simiele M, Lucchiarini M, Alcantarini C, Tettoni MC, Trentini L, Mengozzi G, D'Avolio A, Di Perri G, Bonora S. Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment. **AIDS** 2016.
146. Livelli A, Orofino GC, Calcagno A, Farenga M, Penoncelli D, Guastavigna M, Carosella S, Caramello P, Pia L. Evaluation of a Cognitive Rehabilitation Protocol in HIV Patients with Associated Neurocognitive Disorders: Efficacy and Stability Over Time. **Front Behav Neurosci** 2015.
147. Andreoni M, Marcotullio S, Puro V, De Carli G, Tambussi G, Nozza S, Gori A, Rusconi S, Santoro MM, Clementi M, Perno CF, d'Arminio Monforte A, Maggiolo F, Castagna A, De Luca A, Galli M, Giacomelli A, Borderi M, Guaraldi G, Calcagno A, Di Perri G, Bonora S, Mussini C, Di Biagio A, Puoti M, Bruno R, Zuccaro V, Antinori

- A, Cinque P, Croce D, Restelli U, Rizzardini G, Lazzarin A. An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaimProject. **New Microbiol** 2015.
148. Calcagno A, Cusato J, Marinaro L, Trentini L, Alcantarini C, Mussa M, Simiele M, D'Avolio A, Di Perri G, Bonora S. Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines. **Pharmacogenomics J** 2015.
149. Calcagno A, Montrucchio C, Capetti A, Guaraldi G, Cenderello G, Calza L, Lanzafame M, Marinaro L, Tettoni MC, Trentini L, D'Avolio A, Di Perri G, Bonora S. Raltegravir plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-positive Patients: Safety, Efficacy and Pharmacokinetics. **Curr HIV Res** 2015.
150. Calcagno A, Trentalange A, Simiele M, Marinaro L, Patti F, Tettoni MC, Trentini L, Di Perri G, D'Avolio A, Bonora S. Rilpivirine Pharmacokinetics in 3 HIV-Positive Patients With Liver Cirrhosis Concomitantly Receiving Pantoprazole. **Ther Drug Monit** 2015.
151. Calcagno A, Atzori C, Romito A, Vai D, Audagnotto S, Stella ML, Montrucchio C, Imperiale D, Di Perri G, Bonora S. Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients. **J Neurovirol** 2015.
152. Siccardi M, Olagunju A, Simiele M, D'Avolio A, Calcagno A, Di Perri G, Bonora S, Owen A. Class-specific relative genetic contribution for key antiretroviral drugs. **J Antimicrob Chemother** 2015.
153. Bonora S, Rusconi S, Calcagno A, Bracchi M, Viganò O, Cusato J, Lanzafame M, Trentalange A, Marinaro L, Siccardi M, D'Avolio A, Galli M, Di Perri G. Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). **J Antimicrob Chemother** 2015.
154. Calcagno A, Motta I, Ghisetti V, Lo Re S, Alice T, Marinaro L, Milia MG, Tettoni MC, Trentini L, Orofino G, Salassa B, Di Perri G, Bonora S. HIV-1 Very Low Level Viremia is Associated with Virological Failure in HAART-treated Patients. **AIDS Res Hum Retroviruses** 2015.
155. Calcagno A, D'Avolio A, Bonora S. Pharmacokinetic and pharmacodynamic evaluation of Raltegravir and Experience from Clinical Trials in HIV-positive Patients. **Expert Opinion On Drug Metabolism and Toxicology** 2015.
156. Baietto L, Calcagno A, Motta I, Baruffi K, Poretti V, Di Perri G, Bonora S, D'Avolio A. A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs. **J Antimicrob Chemother** 2015.
157. Simiele M, Carcieri C, De Nicolò A, Ariaudo A, Sciandra M, Calcagno A, Bonora S, Di Perri G, D'Avolio A. A LC-MS method to quantify tenofovir urinary concentrations in treated patients. **J Pharm Biomed Anal** 2015.
158. Calcagno A, Nozza S, Muss C, Celesia BM, Carli F, Piconi S, De Socio GV, Cattelan AM, Orofino G, Ripamonti D, Riva A, Di Perri G. Ageing with HIV: a multidisciplinary review. **Infection** 2015.
159. Cerrato E, Calcagno A, D'Ascenzo F, Biondi-Zoccai G, Mancone M, Grosso Marra W, Demarie D, Omedè P, Abbate A, Bonora S, Di Nicolantonio JJ, Estrada V, Escaned J, Moretti C, Gaita F. Cardiovascular disease in HIV patients: from bench to bedside and backwards. **Open Heart** 2015. *Not Impacted*.

160. D'Ascenzo F, Cerrato E, Calcagno A, Grossomarra W, Ballocca F, Omedè P, Montefusco A, Veglia S, Barbero U, Gili S, Cannillo M, Pianelli M, Mistretta E, Raviola A, Salera D, Garabello D, Mancone M, Estrada V, Escaned J, De Marie D, Abbate A, Bonora S, Zoccai GB, Moretti C, Gaita F. High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysis. **Atherosclerosis** 2015.
161. Ghisetti V, Calcagno A, Burdino E, Orofino G, Bonora S. Acute HIV infection: Improved algorithms for HIV testing. **J Clin Virol** 2015.
162. Calcagno A, Motta I, Milia M, Rostagno R, Simiele M, Libanore V, Fontana S, D'Avolio A, Ghisetti V, Di Perri G, Bonora S. Dried Plasma/Blood Spots for Monitoring Antiretroviral Treatment Efficacy and Pharmacokinetics: a Cross-sectional Study in Rural Burundi. **Br J Clin Pharmacol** 2015.
163. Calcagno A, Simiele M, Alberione MC, Bracchi M, Marinaro L, Ecclesia S, Di Perri G, D'Avolio A and Bonora S. Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-positive Patients are Associated with Compartmental Viral Control. **Clin Infect Dis** 2015.
164. Baietto L, D'Avolio A, Cusato J, Pace S, Calcagno A, Motta I, Corcione S, Di Perri G, De Rosa FG. Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. **J Antimicrob Chemother** 2014.
165. Calcagno A, Di Perri G, Bonora S. Pharmacokinetics and Pharmacodynamics of Antiretrovirals in the Central Nervous System. **Clinical Pharmacokinetics** 2014.
166. Trentalange A, Calcagno A, Raviolo S, Prochet A, Audagnotto S, Ghisetti V, Di Perri G and Bonora S. Cytomegalovirus Central Nervous System Compartmentalization in a Patient Presenting with AIDS. **Antiviral therapy** 2014.
167. Bonora S, Calcagno A, Viganò O, Bigliano P, Marinaro L, Colella E, Orofino G, Trentini L, Tettoni MC, D'Avolio A, Mercadante S, Galli M, Di Perri G and Rusconi S. Efficacy, Tolerability and Virological Consequences of Long-term Use of Unboosted Atazanavir plus 2 NRTIs in HIV-infected Patients. **Current HIV Research** 2014.
168. Calcagno A, Baietto L, Pagani N, Simiele M, Audagnotto S, D'Avolio A, De Rosa FG, Di Perri G and Bonora S. Voriconazole and Atazanavir: a CYP 2C19-dependant Manageable Drug to Drug Interaction. **Pharmacogenomics** 2014.
169. Cannillo M, D'Ascenzo F, Grosso Marra W, Cerrato E, Calcagno A, Omedè P, Bonora S, Mancone M, Vizza D, Di Nicolantonio JJ, Pianelli M, Barbero U, Gili S, Annone U, Raviola A, Salera D, Mistretta E, Vilardi I, Colaci C, Abbate A, Zoccai GB, Moretti C, Gaita F. Heart failure in patients with human immunodeficiency virus: a review of the literature. **J Cardiovasc Med (Hagerstown)** 2014.
170. Lanzafame M, Bonora S, Lattuada E, Calcagno A, Di Perri G, Concia E. Disappearance of renal stones in a HIV-1-infected patient after reduction of atazanavir dose. **AIDS Res Hum Retroviruses** 2014.
171. D'Avolio A, Carcieri C, Cusato J, Simiele M, Calcagno A, Allegra S, Sciandra M, Trentini L, Di Perri G, Bonora S. Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. **J Antimicrob Chemother** 2014.
172. D'Ascenzo F, Quadri G, Cerrato E, Calcagno A, Omedè P, Grosso Marra W, Abbate A, Bonora S, Biondi Zoccai G, Moretti C, Gaita F. A meta-analysis investigating incidence and features of stroke in HIV-infected patients in the highly active antiretroviral therapy era. **J Cardiovasc Med (Hagerstown)** 2014.

173. Calcagno A, Alberione MC, Romito A, Imperiale D, Ghisetti V, Audagnotto S, Lipani F, Raviolo S, Di Perri G, Bonora S. Prevalence and predictors of blood-brain barrier damage in the HAART era. **J Neurovirol. 2014.**
174. D'Ascenzo F, Cerrato E, Appleton D, Moretti C, Calcagno A, Abouzaki N, Vetovec G, Lhermusier T, Carrie D, Das Neves B, Escaned J, Cassese S, Kastrati A, Chinaglia A, Belli R, Capodanno D, Tamburino C, Santilli F, Parodi G, Vachiat A, Manga P, Vignali L, Mancone M, Sardella G, Fedele F, Di Nicolantonio JJ, Omedè P, Bonora S, Gaita F, Abbate A, Biondi Zoccai G. Prognostic Indicators for Recurrent Thrombotic Events in HIV-infected Patients With Acute Coronary Syndromes: Use of Registry Data From 12 sites in Europe, South Africa and the United States. **Thrombosis Research 2014.**
175. Calcagno A, Marinaro L, Nozza S, Aldieri C, Carbone A, Ghisetti V, Trentalange A, D'Avolio A, Castagna A, Di Perri G and Bonora S. Etravirine Plasma Exposure is Associated with Virological Efficacy in Treatment-experienced HIV-positive Patients. **Antiviral Res 2014.**
176. Calcagno A, Lamorde M, D'Avolio A and Bonora S. Personalizing HIV Therapeutics in Resource-Limited Rural Communities: Lessons Learned From the Use of New Tools in Africa. **Current Pharmacogenomics and Personalized Medicine 2014. Not Impacted**
177. De Nicolò A, Simiele M, Calcagno A, Abdi AM, Bonora S, Di Perri G and D'Avolio A. Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitors regimens. **Antimicrob Agents Chemother 2014.**
178. Calcagno A, Nozza S, Simiele M, Milia MG, Chiappetta S, D'Avolio A, Ghisetti V, Lazzarin A, Di Perri G, Bonora S. Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients. **J Antimicrob Chemother 2014.**
179. De Nicolò A, Simiele M, Calcagno A, Mohamed Abdi A, Bonora S, Di Perri G, D'Avolio A. Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitors regimens. **Antimicrob Agents Chemother 2014.**
180. Corcione S, Cardellino CS, Calcagno A, Fossati L, Costa C, Cavallo R, Di Perri G, De Rosa FG. Health-care Associated KPC-BSI: The Time Has Come. **Clin Infect Dis 2014.**
181. Salizzoni S, D'Ascenzo F, Moretti C, Bonora S, Calcagno A, Omedè P, Montrucchio C, Cerrato E, Colaci C, Sheiban I, Marra S, Rinaldi M, Gaita F. Transcatheter aortic valve implantation in a 54-year-old patient with aggressive HIV. **World J Clin Cases 2014. Not Impacted**
182. Marchetti G, Cozzi-Lepri A, Tincati C, Calcagno A, Ceccherini-Silberstein F, De Luca A, Antinori A, Castagna A, Puoti M, Monforte Ad; Iona Foundation Study Group. Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Iona Foundation study. **BMC Infect Dis 2014.**
183. Nozza S, Bigoloni A, Calcagno A, Galli L, Pignataro AR, D'Avolio A, Carbone A, Ripa M, Bonora S, Lazzarin A, Castagna A. Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. **J Antimicrob Chemother 2014.**
184. De Francia S, D'Avolio A, Ariaudo A, Pirro E, Piccione F, Simiele M, Fava C, Calcagno A, Di Perri G, Saglio G. Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia. **Ther Drug Monit 2014.**

185. Calcagno A, D'Avolio A, Di Perri G and Bonora S. Comment on "Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral therapy is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid". **J Acquir Immune Defic Syndr** 2013.
186. Calcagno A, Cusato J, Simiele M, et al. High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. **J Antimicrob Chemother** 2014.
187. Ruggiero T, De Rosa F, Cerutti F, Pagani N, Alice T, Stella ML, Milia MG, Calcagno A, Burdino E, Gregori G, Urbino R, Di Perri G, Ranieri MV, Ghisetti V. A(H1N1)pdm09 hemagglutinin D222G and D222N variants are frequently harbored by patients requiring extracorporeal membrane oxygenation and advanced respiratory assistance for severe A(H1N1)pdm09 infection. **Influenza Other Respi Viruses** 2013.
188. Calcagno A, Baietto L, Pagani N, et al. Pharmacokinetics of caspofungin increased dosage in a patient on rifampin-containing anti-tubercular treatment. **Scand J Infect Dis** 2013.
189. D'Avolio A, Cusato J, Calcagno A and Di Perri G. Estimating Ribavirin plasma exposure: genetics or therapeutic drug monitoring? **J Hepatol** 2013.
190. Calcagno A, Trentini L, Marinaro L, Montrucchio C, D'Avolio A, Ghisetti V, Di Perri G, Bonora S. Transplacental passage of etravirine and maraviroc in a multidrug-experienced HIV-infected woman failing on darunavir-based HAART in late pregnancy. **J Antimicrob Chemother** 2013.
191. Calcagno A, Nozza S, de Requena DG, Galli A, D'Avolio A, Simiele M, Chiappetta S, Di Perri G, Lazzarin A, Bonora S. Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naive patients. **J Antimicrob Chemother** 2013.
192. Calcagno A, Boglione L, De Rosa FG, Di Perri G, Bonora S. Elimination Half-Life May Explain the Relative Efficacy of Boceprevir and Telaprevir in the Treatment of Hepatitis C Virus Genotype 1. **Clin Infect Dis** 2013.
193. Calcagno A, Gonzalez de Requena D, Simiele M, D'Avolio A, Tettoni M, Salassa B, Orofino G, Bramato C, Libanore V, Motta I, Bigliano P, Orsucci E, Di Perri G, Bonora S. Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-sectional Study in HIV-positive Patients with Normal Renal Function. **Antimicrob Agents Chemother** 2013.
194. Santoro MM, Armenia D, Alteri C, Flandre P, Calcagno A, Santoro M, Gori C, Fabeni L, Bellagamba R, Borghi V, Forbici F, Latini A, Palamara G, Libertone R, Tozzi V, Boumis E, Tommasi C, Pinnetti C, Ammassari A, Nicastrì E, Buonomini A, Svicher V, Andreoni M, Narciso P, Mussini C, Antinori A, Ceccherini-Silberstein F, Di Perri G, Perno CF. Impact of pre-therapy viral load on virological response to modern first-line HAART. **Antivir Ther** 2013.
195. Cerrato E, D'Ascenzo F, Biondi-Zoccai G, Calcagno A, Frea S, Grosso Marra W, Castagno D, Omedè P, Quadri G, Sciuto F, Presutti D, Frati G, Bonora S, Moretti C, Gaita F. Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. **Eur Heart J** 2013.
196. Calcagno A, Tettoni MC, Simiele M, Trentini L, Montrucchio C, D'Avolio A, Di Perri G, Bonora S. Pharmacokinetics of 400 mg of raltegravir once daily in

- combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. **J Antimicrob Chemother 2013.**
197. Rekić D, Röshammar D, Bergstrand M, Tarning J, Calcagno A, D'Avolio A, Ormaasen V, Vigan M, Barrail-Tran A, Ashton M, Gisslén M, Abelö A. External Validation of the Bilirubin-Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients. **AAPS J 2013.**
198. D'Avolio A, Simiele M, Calcagno A, Siccardi M, Larovere G, Agati S, Baietto L, Cusato J, Tettoni M, Sciandra M, Trentini L, Di Perri G, Bonora S. Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. **J Antimicrob Chemother 2012.**
199. D'Avolio A, Ciancio A, Siccardi M, Smedile A, Simiele M, Cusato J, Baietto L, Marucco DA, Cariti G, Calcagno A, Gonzalez de Requena D, Sciandra M, Troshina G, Caviglia GP, Bonora S, Rizzetto M, Di Perri G. Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment. **Ther Drug Monit 2012.**
200. Calcagno A, Rostagno R, Di Perri G. Anti-CD20 antibody therapy for B-cell lymphomas. **N Engl J Med 2012.**
201. Bibas M, Lorenzini P, Cozzi-Lepri A, Calcagno A, di Giambenedetto S, Costantini A, Castagna A, Manfrin V, Monforte AD, Antinori A; for the ICONA Cohort Study Group. Polyclonal serum free light chains elevation in HIV-infected patients. **AIDS 2012.**
202. Calcagno A, Yilmaz A, Cusato J, Simiele M, Bertucci R, Siccardi M, Marinaro L, D'Avolio A, Di Perri G, Bonora S. Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. **AIDS. 2012.**
203. D'Avolio A, De Nicolò A, Simiele M, Turini S, Agnesod D, Boglione L, Cusato J, Baietto L, Cariti G, Calcagno A, Sciandra M, Di Perri G, Bonora S. Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients. **J Pharm Biomed Anal. 2012.**
204. Calcagno A, D'Avolio A, Simiele M, Cusato J, Rostagno R, Libanore V, Baietto L, Siccardi M, Bonora S and Di Perri G. Influence of CYP2B6 and ABCB1 SNPs on Nevirapine Plasma Concentrations in Burundese HIV-positive Patients Using Dried Sample Spots Devices. **British Journal of Clinical Pharmacology 2012.**
205. D'Avolio A, Ciancio A, Siccardi M, Smedile A, Baietto L, Simiele M, Aguilar Marucco D, Cariti G, Calcagno A, Gonzalez de Requena D, Sciandra M, Cusato J, Troshina M, Bonora S, Rizzetto M and Di Perri G. ITPA polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associated anaemia in patients under standard anti-HCV treatment. **Therapeutic Drug Monitoring 2012.**
206. Bonora S, Calcagno A, Cometto C, Fontana S, Aguilar D, D'Avolio A, Gonzalez de Requena D, Maiello A, Dal Conte I, Lucchini A and Di Perri G. Short Term Additional Enfuvirtide Therapy is Associated with a Greater Immunological Recovery in HIV Very Late Presenters: a Controlled Pilot Study. **Infection 2012.**
207. Siccardi M, D'Avolio A, Rodriguez-Novoa S, Simiele M, Baietto L, Calcagno A, Moss D, Back D, Owen A, Bonora S and Di Perri G. Intra and inter patient pharmacokinetic variability of raltegravir in the clinical setting. **Therapeutic Drug Monitoring 2012.**

208. D'Avolio, Ciancio A, Siccardi M, Baietto L, Simiele M, Cariti G, Calcagno A, Smedile A, Cusato J, Bonora S, Rizzetto M and Di Perri G. Ribavirin Pharmacokinetics and IL28 plus CYP27B1 SNPs as predictors of response to Peg-IFN/RBV treatment in HCV ¼ infected patients. **Hepatology 2011.**
209. Calcagno A, Bonora S, Simiele M, Rostagno R, Tettoni MC, Bonasso M, Romito A, Imperiale D, D'Avolio A and Di Perri G. Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. **AIDS 2011.**
210. Calcagno A, Nozza S, Bonora S, Castagna A, Gonzalez de Requena D, D'Avolio A, Lazzarin A and Di Perri G. Pharmacokinetics of the Raltegravir/Maraviroc/Etravirine Combination. **J Antimicrob Chemother 2011.**
211. Bonora S, Gonzalez de Requena D, D'Avolio A, Calcagno A, Tettoni MC, Siccardi M, Baietto L, Simiele M, Trentini L, Di Perri G. Pharmacokinetics of switching unboosted Atazanavir co-administered with Tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. **Antiviral Therapy 2011.**
212. Gonzalez de Requena D, Bonora S, Viganò O, Calcagno A, Cometto C, D'Avolio A, Baietto L, Ghisetti V, Magnani S, Ferramosca S, Vitiello P, Galli M, Rusconi S, Di Perri G. Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. **J Antimicrob Chemother 2011.**
213. Calcagno A, Baietto L, De Rosa FG, Tettoni MC, Libanore V, Bertucci R, D'Avolio A, Di Perri G. Posaconazole cerebrospinal concentrations in an HIV-infected patient with brain mucormycosis. **J Antimicrob Chemother 2011.**
214. Lanzafame M, Bonora S, Lattuada E, Calcagno A, Vento S. A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients. **Braz J Infect Dis 2011.**
215. Siccardi M, D'Avolio A, Nozza S, Simiele M, Baietto L, Stefani FR, Moss D, Kwan W, Castagna A, Lazzarin A, Calcagno A, Bonora S, Back D, Di Perri G, Owen A. Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521C>T polymorphism. **Pharmacogenet Genomics 2010.**
216. Calcagno A, Rostagno R, Audagnotto S, D'Avolio A, Bonora S, Ghisetti V, Di Perri G. Is peritoneal fluid a sanctuary site for HIV? **J Antimicrob Chemother 2010.**
217. Calcagno A, Bonora S, D'Avolio A, Siccardi M, Simiele M, Chiesa M, Gonzalez de Requena D, Di Perri G. Raltegravir penetration in seminal plasma of healthy volunteers. **Antimicrob Agents Chemother 2010.**
218. Calcagno A, Bonora S, Bertucci R, Lucchini A, D'Avolio A, Di Perri G. Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients. **AIDS 2010.**
219. Lanzafame M, Hill A, Lattuada E, Calcagno A, Bonora S. Raltegravir: is a 400 mg once-daily dose enough? **J Antimicrob Chemother 2010.**
220. Calcagno A, Bonora S, Tettoni MC, D'Avolio A, Lanzafame M, Penco G, Di Perri G. Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting. **J Acquir Immune Defic Syndr 2009.**
221. Bonora S, Calcagno A, Di Perri G. HIV infection: treatment of naïve patients. **Infez Med 2009. Not Impacted.**
222. Bonora S, Nicastrì E, Calcagno A, Gonzalez de Requena D, D'Ettorre G, Sarmati L, Palmisano L, Vullo V, Di Perri G, Andreoni M. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. **J Med Virol 2009.**

223. Bonora S, Mondo A, Trentini L, Calcagno A, Lucchini A, Di Perri G. Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins. **Journal of Infection 2008.**
224. González de Requena D, Bonora S, Castagna A, Hasson H, Marucco Aguilar D, D'Avolio A, Sciandra M, Trentini L, Calcagno A, Lazzarin A, Di Perri G. Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. **J Antimicrob Chemother 2008.**
225. González de Requena DG, Bonora S, Calcagno A, D'Avolio A, Siccardi M, Fontana S, Milia MG, Sciandra M, Garazzino S, Di Garbo A, Baietto L, Trentini L, Di Perri G. Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens. **Antimicrob Agents Chemother 2008.**
226. Bonora S, Calcagno A, Fontana S, D'Avolio A, Siccardi M, Gobbi F, Di Perri G. Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject. **Clin Infect Dis 2007.**
227. Aguilar Marucco D, Veronese L, de Requena DG, Bonora S, Calcagno A, Cavecchia I, Sinicco A, De Rosa FG, Cariti G, Di Perri G. Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus. **J Antimicrob Chemother 2007.**
228. González de Requena D, Calcagno A, Bonora S, Ladetto L, D'Avolio A, Sciandra M, Siccardi M, Bargiacchi O, Sinicco A, Di Perri G. Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. **AIDS 2006.**
229. Garazzino S, Tettoni M, Calcagno A, D'Avolio A, Bonora S, Di Perri G. Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases. **J Antimicrob Chemother 2006.**
230. Bonora S, Calcagno A, Gonzalez de Requena D, Bargiacchi O, Di Perri G. Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors. **Infez Med 2006. Not Impacted.**

Published articles: 230 (216 with Impact Factor)
 Citations: 2910
 H-index (Scopus): 27
 H-index (Google Scholar): 33
 i10-index (Google Scholar): 126

**Lectures at
 National and
 International
 Conferences**

- Calcagno A. "Putting Theory into Practice – Pharmacogenetics of Tuberculosis Treatment" - EUSAT TB Research – Pharmacogenetics Workshop – Paraguay, March 1st 2023;
- Calcagno A. "PROGRAMMI OSPEDALIERI PER IL CONTROLLO DELLE ICA: Il ruolo del consulente infettivologo" - XXI Congresso Nazionale SIMIT – Roma, 20-23 Novembre 2022;
- Calcagno A. "NTM difficili da trattare" - XXI Congresso Nazionale SIMIT – Roma, 20-23 Novembre 2022;
- Calcagno A. "Clinical severity of omicron variant" – Digital Symposium on SARS-CoV-2: current challenges beyond COVID-19 – 2022;

- Calcagno A. “Pharmacology of the HIV reservoir” – XIV Italian Conference on AIDS and Antiviral Research – Bergamo – 14-16 giugno 2022;
- Calcagno A. “Pharmacological considerations in optimizing care for Patients with Limited Treatment Options” - Managing HIV Patients With Limited Treatment Options 2021 Webinar;
- Calcagno A. “COVID-19 from a recovered healthcare worker’s perspective” – COVID-19 – A IAS Virtual Conference – July 10-11 2020;
- Calcagno A. “Il ruolo delle infezioni virali nelle patologie degenerative del SNC” – XIX Congresso Nazionale SIMIT – Bologna, 13-16 dicembre 2020;
- Calcagno A and Cavassini M. “HIV-associated neurocognitive disorders and neurological complications – An update” – 17th European AIDS Conference – November 6-9 2019, Basel, Switzerland.
- Calcagno A. “Antiretrovirals distribution in sanctuaries” – 11th Italian Conference on AIDS and Antiviral Research – June 5-7, 2019, Milan, Italy.
- Calcagno A. “Last Advances in HIV Pharmacogenomics” - 19th International Workshop on Clinical Pharmacology of Antiviral Therapy, 22 - 24 May 2018, Baltimore, Maryland, USA
- Calcagno A, et al. “Age, Inflammation, Blood Brain Barrier Permeability and Single Nucleotide Polymorphisms in Transporters May Influence Cerebrospinal Fluid Antiretrovirals’ Concentrations” - 19th International Workshop on Clinical Pharmacology of Antiviral Therapy, 22 - 24 May 2018, Baltimore, Maryland, USA
- Calcagno A, et al. “SLC22A2 Genetic Variants and Dolutegravir Trough Concentrations Correlate with Specific Psychiatric Symptoms in HIV-positive Patients on Dolutegravir” - 19th International Workshop on Clinical Pharmacology of Antiviral Therapy, 22 - 24 May 2018, Baltimore, Maryland, USA
- Calcagno A. “La gestione dell’HIV nella popolazione che invecchia” - XVI Congresso Nazionale SIMIT – Salerno 15-18 Ottobre 2017
- Calcagno A. “Asymptomatic CSF Escape” - Seventh International Meeting on HIV Infection of the Central Nervous System – Pollenzo – 12-14th October, 2017
- Calcagno A. “Pharmacokinetic correlates of effective HAART”- 8th Italian Conference on AIDS and Retroviruses, 2016, 6-8 June, Milano, Italy.
- Calcagno A. “Therapeutics of the CNS With HIV Infection”. Conference on Retroviruses and Opportunistic Infections. Boston, MA, US. February 22-25, 2016.
- Calcagno A. “Toxicities in HIV”. 15th European AIDS Conference. October 20th-24th 2015. Barcelona, Spain.
- Calcagno A, et al. “The relevance of CSF PK in managing CNS ART effectiveness”. Sixth International meeting on HIV infection of the Central Nervous System. October 8th-10th 2015, Matera, Italy
- Calcagno A, et al. “Antiretroviral Drug Concentrations in the Central Nervous System: Scarce, Enough or Too Much?”. 7th Italian Conference on AIDS and Retroviruses, 2015, 17-19 May, Riccione, Italy.
- Calcagno A, et al. “Blood Brain Barrier Impairment is Associated with Cerebrospinal Fluid Markers of Neuronal Damage in HIV-positive Patients”7th Italian Conference on AIDS and Retroviruses, 2015, 17-19 May, Riccione, Italy.

- Calcagno A, et al. "Concordance Among Cardiovascular Risk Scores in HIV-positive Patients: Framingham, D:A:D and Progetto Cuore". 6th Italian Conference on AIDS and Retroviruses, 2014, 25-27 May, Roma, Italy.
- Calcagno A, et al. "Level of HIV Viremia Below 50 copies/ml Predicts Virologic Rebound in HAART-treated Patients". 14th Conference of the European AIDS Clinical Society, Bruxelles, Belgium. 16-19 October, 2013.
- Calcagno A, et al. "High Incidence of Cytomegalovirus Reactivation in HIV-positive Patients Treated for Haematological Malignancies". 5th Italian Conference on AIDS and Retroviruses, 2013, 12-14 May, Torino, Italy.
- Calcagno A, et al. "Cerebrospinal Fluid Concentrations Above Drugs IC95s are Associated With CSF Viral Loads Below 50 copies/ml". 14th International Workshop on Clinical Pharmacology of HIV Treatment, Amsterdam, Netherlands, 22-24 April 2013.
- Calcagno A, et al. "Measurement of CSF tau, phosphorylated tau and β -amyloid (1-42) in HIV-positive patients at different stages of infection." 4th Italian Conference on AIDS and Retroviruses, 2012, Naples, Italy.
- Calcagno A "TB, poly-pharmacy and Drug Interactions". EACS Pre-Educational Course, 13th European AIDS Conference, October 12-15, 2011 - Belgrade, Serbia
- Calcagno A, et al. "Monitoring of Virological and Pharmacological Cerebrospinal Fluid Parameters in HAART-treated HIV-positive Patients in the Clinical Setting". ICAR 2011, Florence, Italy.
- Calcagno A, et al. "A Filter-based Cross-sectional Analysis of a HIV Positive HAART-treated Cohort in Rural Burundi: Pharmacokinetics, Pharmacogenetics and Viral Load". HIV10, 10th International Congress on Drug Therapy in HIV Infection, Glasgow, Glasgow, Regno Unito, November 2010.
- Calcagno A, et al. "Raltegravir in the CSF: is Cmax more appropriate than Ctough?". 3rd Meeting on HIV Infection and the Central Nervous System, Stresa, Italy, October 2009.
- Calcagno A, et al. "La Rinascita degli Inibitori Non Nucleosidici". Convegno Nazionale SIMIT, Società Italiana di Malattie Infettive, Modena, Italia, Novembre 2009.
- Calcagno A, et al. "Greater immunological recovery associated with additional enfuvirtide in the treatment of naïve HIV-infected patients at very advanced disease stages: results of a randomized, controlled, pilot study". 1st Italian Conference on AIDS and Retroviruses, 2009, Milano, Italy.
- Calcagno A, et al. "Effect of Darunavir (DRV) genotypic inhibitory quotient (glQ) on the virological response to DRV-containing salvage regimens at 24 weeks". IWCPHT, 9th International Workshop on Clinical Pharmacology of HIV Treatment, New Orleans, USA, 2008.

Books

Participated in the writing of the Chapter "Clinical Treatment Options and Randomized Clinical Trials for Neurocognitive Complications of HIV Infection: Combination Antiretroviral Therapy, Central Nervous System Penetration Effectiveness, and Adjuvants" in the book "Neurocognitive Complications of HIV-Infection" Springer. Editors: Lucette A. Cysique and Sean B. Rourke | ISBN: 978-3-030-80758-0.

Co-Wrote the chapter "Aging with HIV and Oxidative stress", in the book "HIV/AIDS, Oxidative Stress and Dietary Antioxidants" Elsevier. Editors: Victor Preedy Ronald Watson. ISBN: 9780128098530.

Wrote the chapter "Antiretroviral Drug Penetration into the CNS Compartment" in the printed and online "Encyclopedia of AIDS" Springer. Editors: Thomas J. Hope, Mario Stevenson, Douglas Richman. ISBN: 978-1-4614-9610-6 (Online)

Partecipated in the writing of the chapter "Natural History of HIV Infection and Evoluton of Antiretroviral Therapy" in the book "Cardiovascular Disease in AIDS", Springer-verlag Italia S.r.l., 2008, Barbaro G, Boccara F and Skolnik PR.

Partecipated in the writing of the chapter "Donovanosis" in the book "Infezioni Genitali: Aspetti patogenetici, clinici e diagnostici", Latino MA, Magliano E, AMCLI, Milano, 2009.

Torino, Italy; March 2nd 2023
CALCAGNO ANDREA



*Autorizzo il trattamento dei miei dati personali ai sensi dell'art. 13 d. lgs. 30 giugno 2003 n°196-
"Codice in materia di protezione dei dati personali" e dell'art. 13 GDPR 679/16 – "Regolamento
europeo sulla protezione dei dati personali*

Torino, Italy; March 2nd 2023
CALCAGNO ANDREA

